Colitis - Pipeline Review, H1 2019

Date: February 1, 2019
Pages: 117
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CAB50342D57EN
Leaflet:

Download PDF Leaflet

Colitis - Pipeline Review, H1 2019
Colitis - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 24, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns GlobalData requires using corporate email address.
Introduction
Colitis - Overview
Colitis - Therapeutics Development
Colitis - Therapeutics Assessment
Colitis - Companies Involved in Therapeutics Development
Colitis - Drug Profiles
Colitis - Dormant Projects
Colitis - Discontinued Products
Colitis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Colitis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd.1), H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd.1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Colitis - Pipeline by AlfaSigma SpA, H1 2019
Colitis - Pipeline by Apollo Endosurgery Inc, H1 2019
Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2019
Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
Colitis - Pipeline by enGene Inc, H1 2019
Colitis - Pipeline by Genfit SA, H1 2019
Colitis - Pipeline by Handa Pharmaceuticals LLC, H1 2019
Colitis - Pipeline by Immodulon Therapeutics Ltd, H1 2019
Colitis - Pipeline by Immuron Ltd, H1 2019
Colitis - Pipeline by Inflazome Ltd, H1 2019
Colitis - Pipeline by Nippon Kayaku Co Ltd, H1 2019
Colitis - Pipeline by Ogeda SA, H1 2019
Colitis - Pipeline by Principia Biopharma Inc, H1 2019
Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2019
Colitis - Pipeline by RDD Pharma Ltd, H1 2019
Colitis - Pipeline by Saniona AB, H1 2019
Colitis - Pipeline by Scholar Rock Inc, H1 2019
Colitis - Pipeline by Soligenix Inc, H1 2019
Colitis - Pipeline by Synthetic Biologics Inc, H1 2019
Colitis - Pipeline by Vitality Biopharma Inc, H1 2019
Colitis - Dormant Projects, H1 2019
Colitis - Dormant Projects, H1 2019 (Contd.1), H1 2019
Colitis - Dormant Projects, H1 2019 (Contd.2), H1 2019
Colitis - Discontinued Products, H1 2019

LIST OF FIGURES

Number of Products under Development for Colitis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

AlfaSigma SpA
Apollo Endosurgery Inc
Concenter BioPharma Silkim Ltd
Dr. Falk Pharma GmbH
enGene Inc
Genfit SA
Handa Pharmaceuticals LLC
Immodulon Therapeutics Ltd
Immuron Ltd
Inflazome Ltd
Nippon Kayaku Co Ltd
Ogeda SA
Principia Biopharma Inc
Protagonist Therapeutics Inc
RDD Pharma Ltd
Saniona AB
Scholar Rock Inc
Soligenix Inc
Synthetic Biologics Inc
Vitality Biopharma Inc
Skip to top


Ask Your Question

Colitis - Pipeline Review, H1 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: